The next-generation sequencers market is expected to grow at a CAGR of 7.35% during the projected period from 2025 to 2030.
Next-generation sequencing (NGS) is a massively parallel sequencing technology that enables scalability, ultra-high throughput, and quick speed. It can be used to establish the order of the nucleotides in the complete genome. DNA pre-sequencing is one of the most crucial steps in the entire sequencing methodology, which involves preparing the material for the following sequencing reaction. Globally, NGS is being gradually included in clinical laboratory analysis, testing, and illness diagnosis. Pharmacogenomics has made extensive efforts to speed up the drug discovery process. Genome mapping programs, next-generation sequencing applications, healthcare spending, and technology improvements are the main factors driving the next-generation sequencers market growth during the projected period.
Next-generation sequencing market is increasing as the nucleotides in the entire genome can be determined using NGS. As it includes preparing the material for the following sequencing reaction, DNA pre-sequencing is one of the most important processes in the sequencing protocol. Globally, NGS is being gradually included in medical laboratory analysis, evaluation, and illness diagnosis. Pharmacogenomics has extensively used NGS to speed up the drug discovery process.
The rising key development and innovations by the market players in advancing diagnosis are expected to promote the market's overall expansion in the coming years. For instance, in March 2023, SOPHiA GENETICS collaborated with Qiagen to improve tumor analysis using NGS. The agreement paired QIAseq reagent technology with the DDM platform. Customers will be able to obtain QIAseq panels processed by SOPHiA DDM™, a cloud-based platform that analyses data from diverse sources to enable completely new research perspectives, thanks to the agreement. The partnership will initially support homologous recombination repair (HRR), a unique biomarker test to find tumors with specific mutations that may make them vulnerable to PARP inhibitors in oncology, using QIAseq Targeted DNA Pro panels for somatic variant detection.
A significant portion of the sequencing by synthesis technology system can be attributed to the growing accessibility of NGS systems built on this technology.
The ion semiconductor sequencing, on the other hand, is anticipated to expand quickly throughout the projected period. Ion semiconductor sequencing equipment is more sophisticated and affordable than other DNA sequencing techniques, impacting sector growth. Thus, the broad range of applications for the ion semiconductor sequencing technique will fuel the development of the NGS industry. For instance, Next-generation sequencing technology developed by Illumina, known as sequencing by synthesis, is widely used worldwide. Massively parallel sequencing is supported by Illumina sequencing equipment and supplies utilizing a unique technique that recognizes single bases as they are inserted into developing DNA strands.
One of the main factors influencing segmental growth is the rising use of targeted re-sequencing in oncology research. As it can aid researchers in efficiently and successfully analyzing the cancer genome, targeted re-sequencing is being utilized more frequently to examine the cancer genome. In the upcoming years, this trend is anticipated to persist and foster segmental expansion. The segment's growth rate is also accelerated by an expanding number of technological breakthroughs in targeted re-sequencing and its growing use in clinical applications, further promoting the next-generation sequencers market share.
The next-generation sequencers’ market size is hampered due to the vast amount of data created by next-generation sequencing, as well as its administration and interpretation. NGS still presents great obstacles in data storage, processing, quality control management, and interpretation, slowing the transition from the bench to the bedside despite enormous advances in expanding NGS applications from research to clinic. The market expansion of next-generation sequencing is also constrained by the absence of built-in infrastructure for next-generation sequencing because it is an advanced technology that requires significant startup expenses and expert labor, making it expensive to invest.
Geography-wise, the next-generation sequencers market is divided into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is anticipated to be a significant next-generation sequencers marketplace globally. The next-generation sequencer market is anticipated to be dominated by North America, and this trend is anticipated to last for several more years. The use of NGS technology in routine clinical diagnostic tests is growing in popularity. This industry’s growth is expected to be boosted by elements including the rising prevalence of infectious and chronic diseases, rising genomics spending, and rising advances by major industry competitors. For instance, the Canadian Cancer Society predicts that in 2024, 6,600 Canadians will be diagnosed with leukemia. Further, the US Department of Health and Human Services reported 62,770 new cases in 2024, accounting for 3.1% of all new cancer cases. This will contribute to the demand for innovative solutions for the detection and diagnosis of this condition, leading to market growth during the projected period.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |